London Cartilage Clinic
Explore expert articles on cartilage care, regenerative treatments, and practical recovery advice from our specialist team.
ChondroFiller, injected ultrasound-guided into focal cartilage lesions, polymerises within minutes into a porous hydrogel that recruits the body's stem cells for tissue regeneration. Broad knee cartilage cohorts report 81% good-to-excellent functional improvement, though outcome evidence specific to the patella remains limited.
ChondroFiller, a type I collagen hydrogel known as 'German knee gel', is injected into focal cartilage defects where it recruits the patient's own progenitor cells for tissue remodelling; it is neither a lubricant nor a treatment for generalised osteoarthritis.
When ChondroFiller is injected into the joint, it undergoes pH-triggered gelation; the resulting scaffold recruits the body's own repair cells whilst suppressing MMP-13, the primary cartilage-destroying enzyme.
MACI patients return to desk work within two weeks and normal walking by three months, but return to sport takes closer to a year; the delay reflects how long cartilage graft cells must integrate into the surrounding tissue before the repair can withstand athletic demand.
ChondroFiller achieves 70–85% sustained symptom relief across independent clinical cohorts at five-year follow-up through an acellular collagen scaffold that recruits the patient's own progenitor cells.
Advanced knee osteoarthritis is not a single-tissue disorder: Grade III/IV disease simultaneously damages the articular cartilage (removing structural support) and the synovial membrane (perpetuating inflammation), leaving single-injection treatments unable to address both sites.
